Empagliflozin-d6

Empagliflozin-d6 (BI 10773-d6) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].

Product Specifications

Product Name Alternative

BI 10773-d6

UNSPSC

12352005

Target

Isotope-Labeled Compounds; SGLT

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cancer

Smiles

ClC(C=CC([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2C([2H])([2H])C(C([2H])=C3[2H])=C([2H])C([2H])=C3O[C@H]4CCOC4

Molecular Formula

C23H21D6ClO7

Molecular Weight

456.95

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Nikole J.ByrneBSc, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC Basic Transl Sci. 2017 Aug;2 (4) :347-354.|[3]Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15 (9) :937-943.|[4]Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14 (1) :83-90.|[5]Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11 (1) :e0147391.